New drug shows promise in halting spread of brain cancer

Image
IANS New York
Last Updated : Nov 20 2018 | 12:35 PM IST

Scientists have developed a novel drug that could block glioblastoma -- the deadliest form of brain cancer -- from spreading.

The tissues in our bodies are largely made of fluid. It moves around cells and is essential to normal body function. But in some cases, this fluid may be doing more harm than good.

In people who have glioblastoma, this fluid has a much higher pressure, causing it to move fast and forcing cancer cells to spread.

The AMD3100 drug, which has already been used in clinics, was found effective in stopping the inevitable cancer cell spread, the researchers said.

"I am hopeful that since the drug that we used to block flow stimulation is currently used in patients that maybe clinicians, when they do consider using convection enhanced delivery, will combine that with this drug," said lead author Chase Cornelison, a postdoctoral researcher at the Virginia Polytechnic Institute and State University.

In the study, published in the journal Scientific Reports, the team explored the flow of interstitial fluid -- that surrounds cells in the body -- in the spread of glioma cells.

Composed of circulating cerebrospinal fluid, cellular waste and blood plasma, the interstitial fluid flow has been previously linked with an increased invasion rate of glioblastoma, or brain tumour cells.

The researchers tested the AMD3100 drug and found that it could block the rapid movement of the brain's interstitial fluid flow and the spread of cancer cells.

They also tested the drug on mice with glioblastoma to test how a particular approach to delivering cancer treatment, called convection enhanced delivery, caused glioma cells to invade the rest of the brain.

"It (glioblastoma) is so deadly, and there hasn't been a shift in treatment response in decades. Something needs to change... Looking at fluid flow, maybe there's an answer there that we haven't seen," added Jennifer Munson, Assistant Professor.

--IANS

rt/ksk/bg

Disclaimer: No Business Standard Journalist was involved in creation of this content

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Nov 20 2018 | 12:30 PM IST

Next Story